Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


US grants Pacific Edge patent for melanoma detection


US grants Pacific Edge patent for melanoma detection

4 September 2014

The United States Patent Office has granted Pacific Edge patent protection for 'Prognosis Prediction for Melanoma'. The patent covers the technology being used to develop the melanoma prognostic test that will enable clinicians to distinguish aggressive and life threatening melanomas from those that are not as aggressive.

“It is the aggressive tumours that will kill you” Pacific Edge Chief Executive Officer David Darling says.

The test applies a gene signature to a tissue sample taken from the melanoma to detect its aggressiveness allowing clinicians to prescribe the appropriate level of treatment. Specifically, the test in development identifies aggressiveness in Stage III melanomas.

Pacific Edge partnered with the Ludwig Institute of Cancer Research, the world’s largest not-for-profit cancer research organisation, to develop the technology. This successful partnership has enabled Pacific Edge to develop the prototype product for detecting aggressiveness in Stage III melanomas.

The USA is the third jurisdiction after China and New Zealand to grant patent protection for the ‘Prognosis Prediction for Melanoma’ test that is in the development stage.

The melanoma test is one of several cancer products that the Company has worked up to prototype level prior to focussing resources on the successful launch and further development of its Cxbladder technology for detecting and managing bladder cancer. Cxbladderdetect is now being commercialised in the United States, New Zealand, Australia, and soon in Spain. The second product in the program, Cxbladdertriage, is scheduled for commercial release in New Zealand later this year.

Pacific Edge was founded to use the latest developments in molecular biology to provide actionable diagnosis that can contribute to a clinically meaningful difference in cancer detection and the management of that cancer. It is the driving force of our research and product development program” David Darling says.

“Cxbladder is a prime example. It is a quick, cost effective, non-invasive and highly accurate cancer detection test that enables clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample.”

Pacific Edge’s ongoing development program includes clinical and ‘User Programs’ to validate Cxbladdertriage, a new product positioned to enable physians and clinicians to segregate out patients who have presented to the clinician with blood in their urine, who do not have bladder cancer thereby saving considerable clinical work-up cost. Another of the Company’s products in late-stage development and validation is Cxbladderpredict, a product that will enable clinicians to determine the severity of bladder cancer disease and enable them to non-invasively segregate superficial tumours from invasive tumours.

The Company’s portfolio of intellectual property continues to grow and includes patents for a gastric cancer test as well as melanoma and bladder cancers.

“We are now leveraging the experience gained in launching Cxbladder to the world’s largest health care market, the USA, into other products for the USA. We are also now looking to other targeted international markets” David Darling says.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Half Empty: Fonterra's 2017 Opening Forecast Below Expectations

Fonterra Cooperative Group raised its forecast farmgate milk payout for next season by less than expected as the world's largest dairy exporter predicts lower prices will crimp production and supply will pick up. The New Zealand dollar fell. More>>

ALSO:

Pest Control: Mouse Blitz Team Leaves For Antipodes

The Million Dollar Mouse project to rid Antipodes Island of mice is underway with the departure of a rodent eradication team to the remote nature reserve and World Heritage Area. More>>

Gongs Got: Canon Media Awards & NZ Radio Awards Happen

Radio NZ: RNZ website The Wireless, which is co-funded by NZ On Air, was named best website, while Toby Manhire and Toby Morris won the best opinion general writing section for their weekly column on rnz.co.nz and Tess McClure won the best junior feature writer section. More>>

ALSO:

Pre-Budget: Debt Focus Risks Losing Opportunity To Stoke Economy

The Treasury is likely to upgrade its forecasts for economic growth in Budget 2016 next week but Finance Minister Bill English has already signalled that more of his focus is on debt repayment than on fiscal stimulus or tax cuts... More>>

ALSO:

Fulton Hogan's Heroes: Managing Director Nick Miller Resigns

Fulton Hogan managing director Nick Miller will leave the privately owned construction company after seven years in charge. The Dunedin-based company has kicked off a search for a replacement, and Miller will stay on at the helm until March next year, or until a successor has been appointed and a transition period completed. More>>

ALSO:

Gordon Campbell: On Electricity, Executions, And Bob Dylan

The Electricity Authority has unveiled the final version of its pricing plan for electricity transmission. This will change the way transmission prices (which comprise about 10% of the average power bill) are computed, and will add hundreds of dollars a year to power bills for many ordinary consumers. More>>

ALSO:

Half Empty: Fonterra NZ, Australia Milk Collection Drops In Season

Fonterra Cooperative Group says milk collection is down in New Zealand and Australia, its two largest markets, in the first 11 months of the season during a period of weak dairy prices. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news